Text Size
- News Releases
- What's New
- 13 Jul
- Chugai Provides Update on the Phase III IMagyn050 study of Tecentriq in Combination with Chemotherapy and Avastin as a Treatment of Newly-Diagnosed Ovarian Cancer
- 13 Jul
- New Interim Results from Phase IIIb Study Reinforce the Long-Term Safety Profile of Chugai’s Hemlibra in Hemophilia A
- 09 Jul
- Results of Maruho’s Phase III Study with Chugai’s Nemolizumab for Atopic Dermatitis Published in The New England Journal of Medicine Online
- 30 Jun
- Chugai Files a New Drug Application for Polatuzumab Vedotin for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
- 29 Jun
- Chugai’s Enspryng (Satraliazumab) Subcutaneous Injection 120 mg Syringe Approved in Japan for Neuromyelitis Optica Spectrum Disorder
Video Introduction of CHUGAI- Share this site
